CRIPTOP5 and neoplasm: Experimental anti-PD-L1 therapy with Durvalumab significantly increased animals’ survival time and tumor-doubling time, and inhibited metastatic activity in the group of high-grade high-PD-L1(+) GATA3/CR5/6-negative BC PDX acceptors, whereas it had no influence on the mentioned variables in the low-grade group except the number of remote metastasis;